We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division


  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Fecal Calprotectin Predicts Therapy Outcome in Ulcerative Colitis Patients

By LabMedica International staff writers
Posted on 24 Aug 2021
Print article
Image: Schematic representation of calprotectin indications in clinical practices and main advantages (Photo courtesy of Hôpital Beaujon)
Image: Schematic representation of calprotectin indications in clinical practices and main advantages (Photo courtesy of Hôpital Beaujon)
Ulcerative colitis (UC) is a chronic intestinal disorder of unknown etiology and characterized by a relapsing and remitting course. The diagnosis and assessment of the disease activity has been based on clinical symptoms, laboratory measurements, findings of endoscopy and pathological examinations.

The development of a non-invasive and simple biomarker for evaluating the disease activity is considered necessary for the clinical management of UC. Calprotectin is a complex of mammalian proteins found in the cytosol of human neutrophils, monocytes and macrophages. Granulocyte and monocyte adsorptive apheresis (GMA) is widely used as a remission induction therapy for active UC patients.

A large team of Gastroenterologists at the (Asahikawa Medical University, Asahikawa, Japan) and their colleagues conducted a multicenter prospective observation study of patients who received 10 sessions of GMA, twice a week, for five consecutive weeks. A total 36 patients with active UC were enrolled in the study. Fecal calprotectin was measured at entry, one week, two weeks, at the end of GMA and on the day of endoscopy within 24 weeks after GMA.

The patients’ stool samples were homogenized by mixing with a predefined extraction buffer volume. After centrifugation, the supernatants were subjected to a fluorescence enzyme immunoassay using EliA Calprotectin 2 (Thermo Fisher Scientific, Tokyo, Japan). Laboratory values, including the white blood cell (WBC) count and C- reactive protein (CRP) level were also measured at the same time points as FC measurement: at entry, one and two weeks and at the end of GMA and on the day when endoscopy was performed within 24 weeks after GMA. The team analyzed the relationships between the clinical outcome (clinical remission [CR] and endoscopic remission [ER]) and the change in FC concentration.

The investigators reported that the overall CR and ER rates were 50.0% and 19.2%, respectively. After GMA, the median FC concentration in patients with ER was significantly lower than that in patients without ER (469 mg/kg versus 3,107 mg/kg). When the cut-off value of FC concentration was set at 1,150 mg/kg for assessing ER after GMA, the sensitivity and specificity were 0.8 and 0.81, respectively. The FC concentration had significantly decreased by one week. An ROC analysis demonstrated that the reduction rate of FC (ΔFC) at one week was the most accurate predictor of CR at the end of GMA (AUC = 0.852). When the cut-off value of ΔFC was set at ≤ 40% at one week for predicting CR at the end of GMA, the sensitivity and specificity were 76.9% and 84.6%, respectively.

The authors concluded that they had evaluated the utility of FC as a biomarker for assessing ER after GMA and predicting CR in the early phase during GMA in patients with active UC. The findings will benefit patients with active UC by allowing them to avoid unnecessary invasive procedures and will help establish new strategies for GMA. The study was published on August 6, 2021 in the journal BMC Gastroenterology.

Related Links:
Asahikawa Medical University
Thermo Fisher Scientific

Gold Supplier
Multifuge X4 Pro Centrifuge Series
Fluorescence Immunoassay Analyzer
Silver Supplier
Bacteriuria Test Strips
MAST Bacteruritest Strips
Cancer Panel

Print article


Molecular Diagnostics

view channel
Image: Model of the PD-1 (Programmed cell death protein 1) protein. Only a subset of recurrent glioblastomas respond to anti-PD-1 immunotherapy (Photo courtesy of Wikimedia Commons)

Biomarker Predicts Potential Benefit of Checkpoint Inhibitor Therapy for Brain Cancer Patients

A phosphorylated form of ERK (extracellular signal-regulated kinase) protein has been identified as a biomarker that may be used to predict which brain cancer patients might benefit from checkpoint inhibitor... Read more


view channel
Image: The UniCel DxH 800 Coulter Cellular Analysis System (Photo courtesy of Beckman Coulter)

Monocyte Distribution Width Predicts Sepsis in Critically Ill Patients

Sepsis has been reported as a major cause of increased morbidity, length of stay and mortality among patients hospitalized in Intensive Care Units (ICUs) for any cause. The survival of patients developing... Read more


view channel
Image: Procartaplex Immunoassays Kits are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously (Photo courtesy of Thermo Fisher Scientific)

Assay Developed for Patient-Specific Monitoring and Treatment for Ovarian Cancer

Tumors can influence peripheral immune macroenvironment, thereby creating opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and immunotherapy designing.... Read more


view channel
Image: Clinical metagenomics (CMg) using nanopore sequencing (Photo courtesy of Oxford Nanopore Technologies)

Same Day Test Identifies Secondary Infections in COVID-19 Patients

The intensive care unit (ICU) is a dynamic environment with frequent staff-patient contact for invasive monitoring, interventions and personal care that together introduce the risk of secondary or nosocomial... Read more


view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global HBA1c Laboratory Tests Market Driven by Rise in Diabetic Population

The global HBA1c laboratory tests market is projected to expand at a significant pace over the coming years, driven by an increase in the prevalence of diabetes, rise in prescription rate of HBA1c tests... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.